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LETTER TO THE EDITOR
Keratin 6b variant p.Gly499Ser reported in delayed-onset
pachyonychia congenita is a non-pathogenic polymorphism
Dear Editor,
Pachyonychia congenita (PC) is an ultra-rare hereditary skin
disorder primarily characterized by severe, painful and highly
debilitating plantar keratoderma, variable hypertrophic nail dys-
trophy, epidermal cysts, leukokeratosis and other features.1 PC
is caused by heterozygous dominant-negative mutations in any
one of five keratin genes, KRT6A, KRT6B, KRT6C, KRT16 or
KRT17 (encoding the differentiation-specific keratins K6a, K6b,
K6c, K16 or K17, respectively).2 Due to the rarity of PC, some
other genodermatoses with overlapping clinical features can be
misdiagnosed as PC.3
Our laboratory has run an international molecular genetic
diagnostic service for PC in association with the patient advo-
cacy organization Pachyonychia Congenita Project (PC Project;
www.pachyonychia.org) since 2004. As of April 2017, we have
identified 113 distinct pathogenic KRT6A, KRT6B, KRT6C,
KRT16 or KRT17 mutations in 774 individuals from 419 unre-
lated families who are registered in the International Pachyony-
chia Congenita Research Registry (http://www.pachyonychia.
org/pc-data/). With the analysis of a large number of PC
patients, the older classification of PC-1 and PC-2 subtypes
has been shown to be misleading.1 Therefore, the nomencla-
ture has recently been revised and a gene-specific classifica-
tion is recommended (e.g. PC-K6a, PC-K16).2,3
Recently, a novel KRT6B variant (c.1495G>A; p.Gly499Ser)
was reported in The Journal of Dermatology as the causative
mutation in a patient with late-onset PC.4 We believe that this
K6b variant is a non-pathogenic polymorphism. The p.Gly499-
Ser variant in KRT6B is a common single nucleotide polymor-
phism (SNP), present in the dbSNP database under the
accession number (rs61746355; https://www.ncbi.nlm.nih.gov/
projects/SNP/). According to the ExAC database (Exome
Aggregation Consortium, Broad Institute; http://exac.broadinsti
tute.org), in a sample of 60 508 individuals subjected to exome
sequencing, 2960 were heterozygous and 57 were homozy-
gous for the minor allele of the SNP rs61746355, p.Gly499Ser.
This equates to approximately 5% of the population being
either heterozygous or homozygous for the p.Gly499Ser variant
in K6b. This high-frequency SNP is inconsistent with the rarity
of PC. Although Guo and colleagues did not observe this SNP
in 100 control individuals, who are presumed to be of Chinese
ancestry,4 it may be that this SNP is very rare in the Chinese
population but is common in other ancestral groups.
We would recommend that the authors fully sequence all
exons and splice sites of the five keratin genes associated with
PC and cross-reference any detected variations against ExAC
or other online SNP databases to identify the actual causative
mutation. In addition, given that the phenotype is somewhat
unusual and few mutations have been reported in association
with delayed-onset PC previously, it may also be prudent to
consider other genes involved with phenotypes that resemble
PC. Based on the large number of PC patients in the Interna-
tional PC Research Registry, it is highly unusual for a patient to
present only with nail changes, making GJB6, and especially
FZD6, important candidate genes to analyze in this family.1,5
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